114 related articles for article (PubMed ID: 8622086)
41. A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma.
Kreuser ED; Hilgenfeld RU; Matthias M; Hoksch B; Boewer C; Oldenkott B; Knauf WU; Boese-Landgraf J; Schalhorn A; Zeitz M
Semin Oncol; 1992 Apr; 19(2 Suppl 3):197-203. PubMed ID: 1557647
[TBL] [Abstract][Full Text] [Related]
42. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A
Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407
[TBL] [Abstract][Full Text] [Related]
43. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.
Köhne CH; Schöffski P; Wilke H; Käufer C; Andreesen R; Ohl U; Klaasen U; Westerhausen M; Hiddemann W; Schott G; Harstick A; Bade J; Horster A; Schubert U; Hecker H; Dörken B; Schmoll HJ
J Clin Oncol; 1998 Feb; 16(2):418-26. PubMed ID: 9469324
[TBL] [Abstract][Full Text] [Related]
44. Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin.
Fleming GF; O'Brien SM; Hoffman PC; Vokes EE; Vogelzang NJ; Schilsky RL; Waggoner SE; Ratain MJ
Cancer Chemother Pharmacol; 1997; 39(3):227-32. PubMed ID: 8996525
[TBL] [Abstract][Full Text] [Related]
45. [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients].
Zhou ZW; Wang GQ; Wan DS; Pan ZZ; Li S; Chen G; Liao H
Ai Zheng; 2004 Nov; 23(11 Suppl):1512-6. PubMed ID: 15566669
[TBL] [Abstract][Full Text] [Related]
46. Activity of high dose 24 hour 5-fluorouracil infusion plus L-leucovorin in advanced colorectal cancer.
Nobile MT; Barzacch MC; Sanguineti O; Chiara S; Gozza A; Vincenti M; Lavarello A; Cognein P; Lionetto R; Percivale PL; Bertoglio S; Murolo C; Esposito M; Vannozzi MO; Rosso R
Anticancer Res; 1998; 18(1B):517-21. PubMed ID: 9568171
[TBL] [Abstract][Full Text] [Related]
47. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.
Köhne CH; Wils J; Lorenz M; Schöffski P; Voigtmann R; Bokemeyer C; Lutz M; Kleeberg C; Ridwelski K; Souchon R; El-Serafi M; Weiss U; Burkhard O; Rückle H; Lichnitser M; Langenbuch T; Scheithauer W; Baron B; Couvreur ML; Schmoll HJ;
J Clin Oncol; 2003 Oct; 21(20):3721-8. PubMed ID: 12963704
[TBL] [Abstract][Full Text] [Related]
48. Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck.
Hitt R; Jimeno A; Millán JM; Castellano D; Cortés-Funes H
Cancer; 2004 Aug; 101(4):768-75. PubMed ID: 15305408
[TBL] [Abstract][Full Text] [Related]
49. Phase II clinical trial with 5-fluorouracil, recombinant interferon-alpha-2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus.
Wadler S; Haynes H; Beitler JJ; Hu X; Fell S; Camacho M; Levine B; Wiernik PH
Cancer; 1996 Jul; 78(1):30-4. PubMed ID: 8646722
[TBL] [Abstract][Full Text] [Related]
50. Paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: a preliminary report.
Hussain M; Salwen W; Kucuk O; Ensley J
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-43-S19-45. PubMed ID: 9427265
[TBL] [Abstract][Full Text] [Related]
51. Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma.
Grem JL; Jordan E; Robson ME; Binder RA; Hamilton JM; Steinberg SM; Arbuck SG; Beveridge RA; Kales AN; Miller JA
J Clin Oncol; 1993 Sep; 11(9):1737-45. PubMed ID: 8355041
[TBL] [Abstract][Full Text] [Related]
52. A phase I-II trial of carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck.
Forastiere AA; Natale RB; Takasugi BJ; Goren MP; Vogel WC; Kudla-Hatch V
J Clin Oncol; 1987 Feb; 5(2):190-6. PubMed ID: 3543242
[TBL] [Abstract][Full Text] [Related]
53. A phase II trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma.
Kreuser ED; Hilgenfeld RU; Matthias M; Hoksch B; Boewer C; Oldenkott B; Lenk H; Wiener N; Boese-Landgraf J; Schalhorn A
Semin Oncol; 1992 Apr; 19(2 Suppl 4):57-62. PubMed ID: 1553576
[TBL] [Abstract][Full Text] [Related]
54. Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer.
Greco FA; Figlin R; York M; Einhorn L; Schilsky R; Marshall EM; Buys SS; Froimtchuk MJ; Schuller J; Schuchter L; Buyse M; Ritter L; Man A; Yap AK
J Clin Oncol; 1996 Oct; 14(10):2674-81. PubMed ID: 8874326
[TBL] [Abstract][Full Text] [Related]
55. Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. Hellenic Cooperative Oncology Group.
Kosmidis PA; Tsavaris N; Skarlos D; Theocharis D; Samantas E; Pavlidis N; Briassoulis E; Fountzilas G
J Clin Oncol; 1996 Oct; 14(10):2682-7. PubMed ID: 8874327
[TBL] [Abstract][Full Text] [Related]
56. Decreased catabolism of fluorouracil in peripheral blood mononuclear cells during combination therapy with fluorouracil, leucovorin, and interferon alpha-2a.
Yee LK; Allegra CJ; Steinberg SM; Grem JL
J Natl Cancer Inst; 1992 Dec; 84(23):1820-5. PubMed ID: 1433371
[TBL] [Abstract][Full Text] [Related]
57. A phase I study of recombinant human interferon alpha-2b combined with 5-fluorouracil and cisplatin in patients with advanced cancer.
Trudeau M; Zukiwski A; Langleben A; Boos G; Batist G
Cancer Chemother Pharmacol; 1995; 35(6):496-500. PubMed ID: 7882458
[TBL] [Abstract][Full Text] [Related]
58. Relationship between fluorouracil systemic exposure and tumor response and patient survival.
Milano G; Etienne MC; Renée N; Thyss A; Schneider M; Ramaioli A; Demard F
J Clin Oncol; 1994 Jun; 12(6):1291-5. PubMed ID: 8201391
[TBL] [Abstract][Full Text] [Related]
59. Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alfa: evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation.
Sparano JA; Wadler S; Diasio RB; Zhang R; Lu Z; Schwartz EL; Einzig A; Wiernik PH
J Clin Oncol; 1993 Aug; 11(8):1609-17. PubMed ID: 8336197
[TBL] [Abstract][Full Text] [Related]
60. [Population study of dihydropyrimidine dehydrogenase in cancer patients].
Etienne MC; Milano G; Renée N; Lagrange JL; Dassonville O; Thyss A; Schneider M; François E; Fleming R; Demard F
Bull Cancer; 1995 Sep; 82(9):705-10. PubMed ID: 8535028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
